Abeona Therapeutics Q3 2023 Earnings Report
Key Takeaways
Abeona Therapeutics reported a net loss attributable to common shareholders of $11.8 million for the third quarter of 2023. The company's cash, cash equivalents, restricted cash and short-term investments totaled $54.1 million as of September 30, 2023, which is expected to fund operations into the fourth quarter of 2024. The company completed its first-ever U.S. BLA submission and initiated commercial readiness activities for potential U.S. launch of pz-cel.
Completed Abeona’s first-ever U.S. Biologics License Application (BLA) submission in September 2023.
FDA decision on priority review and acceptance of BLA for pz-cel expected by late-November 2023.
Initiated commercial readiness activities for potential U.S. launch of pz-cel.
Cash, cash equivalents, restricted cash and short-term investments totaled $54.1 million as of September 30, 2023.
Abeona Therapeutics
Abeona Therapeutics
Forward Guidance
Abeona estimates that its cash and cash equivalents, restricted cash and short-term investments as of September 30, 2023 are sufficient resources to fund operations into the fourth quarter of 2024.